Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-masked placebo-controlled study of OT-101 (atropine sulfate) ophthalmic solution for pediatric myopia
2020-003976-42Phase 3
- Sponsor
- Ocumension Biotech
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myopia comparing OT-101 atropine ophthalmic solution with Placebo ophthalmic solution (2 arms).
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on 2020-003976-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003976-42.